eTable 1. Results for various drug classes with focus on over-treatment.
|
V1: GOLD 1–4 |
Number of patients (%) | LABA and/or LAMA | ICS | PDE4 inhibitors |
Oral glucocorticoids |
|||||||
|
LABA (mono) |
LABA + ICS |
LABA incl. combination drugs (LABA + ICS oder LABA) |
LAMA (Mono) |
LABA + LAMA incl. combination drugs |
ICS incl. combination drugs (ICS + LABA) |
ICS (mono) |
Triple therapy |
Theophylline | Roflumilast | |||
| A | ||||||||||||
| CAT | 247 (10.8%) |
93 (37.7%) |
79 (32.0%) |
170 (68.8%) |
157 (63.6%) |
124 (50.5%) |
114 (46.2%) |
36 (14.6%) |
80 (32.4%) |
14 (5.7%) |
5 (2.0%) |
11 (4.5%) |
| mMRC | 878 (38.5%) |
317 (36.1%) |
337 (38.4%) |
640 (72.9%) |
556 (63.3%) |
455 (51.8%) |
465 (53.0%) |
133 (15.2%) |
310 (35.3%) |
56 (6.4%) |
36 (4.1%) |
50 (5.7%) |
| B | ||||||||||||
| CAT | 1 207 (52.9%) |
458 (38.0%) |
546 (45.2%) |
982 (81.4%) |
857 (71.0%) |
758 (62.8%) |
743 (61.6%) |
208 (17.2%) |
556 (46.1%) |
120 (9.9%) |
86 (7.1%) |
102 (8.5%) |
| mMRC | 576 (25.3%) |
234 (40.6%) |
288 (50.0%) |
512 (88.9%) |
458 (79.5%) |
427 (74.1%) |
392 (68.1%) |
111 (19.3%) |
326 (56.6%) |
78 (13.5%) |
55 (9.6%) |
63 (10.9%) |
| C | ||||||||||||
| CAT | 41 (1.8%) |
15 (36.6%) |
26 (63.4%) |
39 (95.1%) |
31 (75.6%) |
30 (73.2%) |
31 (75.6%) |
6 (14.6%) |
24 (58.5%) |
2 (4.9%) |
2 (4.9%) |
5 (12.2%) |
| mMRC | 296 (13.0%) |
110 (37.2%) |
169 (57.1%) |
270 (91.2%) |
231 (78.0%) |
214 (72.3%) |
216 (73.0%) |
50 (16.9%) |
170 (57.4%) |
32 (10.8%) |
29 (9.8%) |
39 (13.2%) |
| D | ||||||||||||
| CAT | 786 (34.5%) |
294 (37.4%) |
449 (57.1%) |
724 (92.1%) |
666 (84.7%) |
630 (80.2%) |
612 (77.9%) |
176 (22.4%) |
525 (66.8%) |
130 (16.5%) |
130 (16.5%) |
169 (21.5%) |
| mMRC | 531 (23.3%) |
199 (37.5%) |
306 (57.6%) |
493 (92.8%) |
466 (87.8%) |
214 (72.3%) |
427 (80.4%) |
132 (24.9%) |
379 (71.4%) |
100 (18.8%) |
103 (19.4%) |
135 (25.4%) |
| Gesamt | ||||||||||||
| CAT | 2281 | 860 (37.7%) |
1100 (48.2%) |
1915 (84.0%) |
1711 (75.0%) |
1542 (67.6%) |
1500 (65.8%) |
426 (18.7%) |
1185 (52.0%) |
266 (11.7%) |
223 (9.8%) |
287 (12.6%) |
| mMRC | 2281 | 860 (37.7%) |
1100 (48.2%) |
1915 (84.0%) |
1711 (75.0%) |
1542 (67.6%) |
1500 (65.8%) |
426 (18.7%) |
1185 (52.0%) |
266 (11.7%) |
223 (9.8%) |
287 (12.6%) |
| Guideline-adherent therapy (according to 2017GOLD) |
Guideline-adherent according to 2006 NVL (not 2017 GOLD) |
Over-treatment | Cannot be classified separately |
|||||||||
Absolute frequencies and percentages of various drug classes in the GOLD groups A–D, each both on the basis of CAT and on the basis of mMRC, adding to Table 1. The percentages for the various medications refer to the number of patients in the respective GOLD group, the percentages on the left and lower margins to the analyzable total number of patients (N = 2281). The color codes symbolize that the medication complies with the GOLD criteria (dark blue) or at least is NVL-compliant (light blue) or represents an over-treatment according to 2017 GOLD recommendations (orange) or could not be evaluated with regard to their appropriateness by itself (gray; see text and Table 1). The column totals refer to all patients.
CAT, COPD Assessment Test; ICS, inhaled corticosteroids; LABA, long-acting beta 2 -agonist; LAMA, long-acting muscarinic antagonist; NVL, German National Disease Management Guideline; mMRC, modified Medical Research Council; PDE4 inhibitor, inhibitor of phosphodiesterase 4; Triple, LABA + LAMA + ICS